Ras-related glycolysis inhibitor and calcium channel regulator (RRAD)

RRAD (Ras-related glycolysis inhibitor and calcium channel regulator) is a small GTPase belonging to the Ras superfamily, encoded by the *RRAD* gene. It regulates cellular metabolism, modulates calcium channel trafficking, and is implicated in multiple pathological conditions, including cancer, cardiovascular disease, and diabetes mellitus. RRAD inhibits glycolytic activity in part by preventing the translocation of GLUT1, but its expression and function vary by tissue type and disease context. In cardiac tissue, RRAD regulates excitation-contraction coupling by controlling L-type calcium channel activity, which affects heart rate and contractility. It interacts with key cellular pathways including EGFR/STAT3 and NF-κB, and serves as both a biomarker and potential therapeutic target for diverse conditions. Its targeting is complicated by context-dependent functional duality and broad physiological roles[1][2][3][4][5].

Other names

GTP-binding protein RADRADREM3RAD1Ras associated with diabetesRas-related associated with diabetesRas (RAD and GEM) like GTP binding 3

Drugs or agents that modulate RRAD may inhibit glycolysis by blocking GLUT1 translocation. Suppress NF-κB pathway transcriptional activity. Modulate antiarrhythmic effects by suppressing L-type Ca²⁺ currents. Influence resistance to chemotherapy via EGFR-STAT3 pathway modulation[1].